OxFORD Asset Management LLP increased its position in VIVUS, Inc. (NASDAQ:VVUS) by 14.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,059,382 shares of the biopharmaceutical company’s stock after buying an additional 129,871 shares during the quarter. OxFORD Asset Management LLP owned 1.00% of VIVUS worth $1,040,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in VVUS. Bank of New York Mellon Corp lifted its position in VIVUS by 7.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,564 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 7,722 shares during the last quarter. Russell Investments Group Ltd. lifted its position in VIVUS by 84.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 148,600 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 68,200 shares during the last quarter. Macquarie Group Ltd. bought a new stake in VIVUS in the 3rd quarter worth approximately $192,000. Northern Trust Corp lifted its position in VIVUS by 16.8% in the 2nd quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock worth $335,000 after buying an additional 39,473 shares during the last quarter. Finally, IHT Wealth Management LLC lifted its position in VIVUS by 653.3% in the 2nd quarter. IHT Wealth Management LLC now owns 1,130 shares of the biopharmaceutical company’s stock worth $1,100,000 after buying an additional 980 shares during the last quarter. Institutional investors own 31.30% of the company’s stock.

Separately, ValuEngine upgraded VIVUS from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd.

Shares of VIVUS, Inc. (NASDAQ:VVUS) opened at $0.49 on Thursday. The firm has a market capitalization of $56.15, a P/E ratio of 1.56 and a beta of 0.77. VIVUS, Inc. has a 12-month low of $0.48 and a 12-month high of $1.38. The company has a debt-to-equity ratio of 643.86, a current ratio of 7.47 and a quick ratio of 7.09.

VIVUS (NASDAQ:VVUS) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.07. The company had revenue of $15.19 million during the quarter, compared to the consensus estimate of $16.00 million. VIVUS had a return on equity of 344.23% and a net margin of 26.71%. VIVUS’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.09) EPS. analysts expect that VIVUS, Inc. will post -0.32 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/21/vivus-inc-vvus-shares-bought-by-oxford-asset-management-llp.html.

About VIVUS

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Want to see what other hedge funds are holding VVUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VIVUS, Inc. (NASDAQ:VVUS).

Institutional Ownership by Quarter for VIVUS (NASDAQ:VVUS)

Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.